<DOC>
	<DOCNO>NCT02546388</DOCNO>
	<brief_summary>The purpose research study find drug call OctreoScan help doctor diagnose people cardiac sarcoidosis well . OctreoScan approve U.S. Food Drug Administration ( FDA ) diagnose certain tumor .</brief_summary>
	<brief_title>Somatostatin Receptor Imaging Patients With Suspected Cardiac Sarcoidosis</brief_title>
	<detailed_description />
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Individuals age 18 old Documentation biopsyproven sarcoidosis lung and/or lymph node Clinical suspicion cardiac involvement define presence following : highdegree AV nodal block , complete bundle branch block , reduce leave right ventricular systolic function , cardiac arrhythmia , and/or unexplained chest pain , dyspnea syncope PET/CT image demonstrate abnormal myocardial FDG uptake consistent active inflammatory myocardium . Current use oral steroid immunosuppressive medication , may , theory , suppress OctreoScan uptake heart . Patients history neuroendocrine tumor ( specially insulinomas ) Patients take medication Octreotide Patients total parenteral nutrition ( TPN ) Women pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>